AstraZeneca to bid with Takeda for Israeli biotech incubator
AstraZeneca and Japan's Takeda will bid against Johnson & Johnson and OrbiMed for the Chief Scientist's tender.
The company will bid for the incubator tender against a consortium of OrbiMed venture capital fund and healthcare giant Johnson & Johnson (NYSE: JNJ).
"Globes" understands that in bidding for the incubator AstraZeneca will team up with Takeda Ventures Inc., the venture capital fund of Japanese drug company Takeda Pharmaceuticals Co. Ltd. (TSE: 4502).
The tender bid winner will be announced in the coming few months.
Published by Globes [online], Israel business news - www.globes-online.com - on June 11, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options